Insights from studies on chronic myeloid leukemia (CML) have helped in the development of next-generation FLT3 inhibitors to improve treatment outcomes in AML patients. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.